TITLE

Schering and Bayer seal drug ownership agreement

AUTHOR(S)
Chynoweth, Emma
PUB. DATE
April 2007
SOURCE
ICIS Chemical Business;4/2/2007, Vol. 2 Issue 60, p33
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This article reports that Bayer Schering Pharma and Novartis have settled a dispute over U.S. production of the interferon-based multiple sclerosis treatment Betaseron, sold in the U.S. as Betaferon. The deal sees Bayer Schering Pharma acquiring most of Novartis' Emeryville, California, site, where it will produce the drug for U.S. patients. Bayer Schering will have full control of the manufacturing and process technology and continue to employ the facility's workforce.
ACCESSION #
24889303

 

Related Articles

  • Multiple Sclerosis Update.  // PharmaWatch: CNS;Nov2007, Vol. 6 Issue 11, p5 

    The article reports that Novartis has transferred its manufacturing responsibility to Bayer Schering Pharma for multiple sclerosis drug Betaseron in Emeryville, California. It stated that Novartis has received a total one-time payment of about $200 million for the transfer of production...

  • COMPANY SPOTLIGHT -- Bayer Schering Pharma.  // PharmaWatch: Cancer;Jan2010, Vol. 9 Issue 1, p25 

    The article offers information on business operations of the pharmaceutical company Bayer Schering Pharma AG. It reports Bayer's recent deal with Micromet Inc. for the development of a new antibody called BiTE for tumor treatment, and gives an overview of its foundation, business growth,...

  • Bayer Acquires Facility from Novartis.  // BioPharm International;Nov2007, Vol. 20 Issue 11, p10 

    The article reports on the acquisition of Novartis AG's biologics manufacturing facility by Bayer Schering Pharma AG in the U.S. It relates that the facility will be used by the company to manufacture its multiple sclerosis drug Betaseron. In addition, the company will also extend support to...

  • Bayer acquires manufacturing facility from Novartis.  // PharmaWatch: Biotechnology;Nov2007, Vol. 6 Issue 11, p25 

    The article reports that Bayer Schering Pharma AG has purchased a manufacturing facility from Novartis AG in Emeryville, California. This move is part of a deal to acquire the rights to multiple sclerosis drug Betaseron. Bayer Schering will manufacture and retain full control of all...

  • CNS News Round-Up.  // PharmaWatch: Monthly Review;Nov2007, Vol. 6 Issue 11, p12 

    The article offers updates on treatments for central nervous system diseases. Bayer Schering Pharma AG has acquired a biologics manufacturing facility of Novartis AG. Alexza Pharmaceuticals Inc. will begin the Phase III clinical trial of its staccato loxapine, a treatment for acute agitation....

  • Schering renamed.  // European Pharmaceutical Executive;Feb/Mar2007, p10 

    The article reports on Germany-based Schering AG's decision to change its name to Bayer Schering Pharma AG. The necessary entry in the commercial register took effect on December 29, 2006. The article also reports that the new logo has been mounted on Bayer Schering Pharma's headquarters in...

  • TOP 20 PHARMA: #15 BAYER SCHERING.  // Contract Pharma;2009, Vol. 11 Issue 6, p84 

    The article profiles Bayer Schering Pharma AG, the rank 15 among the top 20 pharmaceutical companies based in Leverkusen, Germany. It notes that it was founded in 1971 and handles 108,600 employees. It mentions its plan to strengthen its research and development initiative in 2009 through its 4...

  • Bayer completes acquisition of U.S biologics manufacturing facility from Novartis.  // Chemical Business;Oct2007, Vol. 21 Issue 10, p75 

    The article reports on the acquisition by Bayer of a biologics manufacturing facility in California from Novartis in October 2007. Under the deal, the drug Betaseron will be manufactured by Bayer, retain all employees involved in the production of the drug. Reportedly, Novartis has also...

  • European pharma consolidation generates quality spinoffs. Sheridan, Cormac // Nature Biotechnology;Dec2006, Vol. 24 Issue 12, p1458 

    The article focuses on the consolidation and acquisition of European pharmaceutical companies. The article discuses that Berlin based Schering company and two German companies are acquired by Bayer Healthcare, Germany, to establish Bayer-Schering Pharma. And the establishment will concentrate on...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics